MD Anderson Cancer Center has completed patient dosing in the second cohort of a Phase 1b investigator-initiated trial of Soricimed Biopharma’s lead drug candidate, SOR-C13, for the targeted treatment of solid tumor cancers.
The trial is proceeding as designed and recruitment for cohort three is currently underway. The objective of the dose escalation part of the Phase 1b trial is to establish the maximum tolerated dose of SOR-C13. Patients in the third cohort of the clinical trial will be dosed at three times the initial test dose.
“We are pleased to see continued positive momentum with respect to this clinical trial and SOR-C13,” Dr. Siqing Fu, M.D. Ph.D., principal investigator and a member of the Department of Investigational Cancer Therapeutics at MD Anderson.
“At each step, we learn more about SOR-C13, building an important foundation that will help inform the potential use of the drug going forward,” he added.
In addition to traditional measurements, patient tumors are being assessed with Image Analysis Group’s advanced imaging to offer clinicians a detailed 3-D model of each of the tumors, helping track the behavior of the cancer cells and more accurately assess treatment effects.
Robert Bruce, CEO of closely-held Soricimed, said the company is encouraged by the data it has seen to date and is deeply committed to continuing to explore SOR-C13 in late-stage solid tumour cancers, where there remains a significant unmet need for new and innovative therapeutic options.
